A retrospective analysis of 25 patients at The Walton Centre in Liverpool has come up with a finding that rituximab lowers the frequency of attacks in patients suffering from neuromyelitis optica and also improves disability in them. Rituximab could be beneficial for patients who have not responded to various immuno-therapies. Authors of the study report that the median post-treatment rate was 0 relapses per year (follow-up of 19 months) as compared to 1.7 relapses before the treatment. The Median Expanded Disability Status Scale scores also improved. A controlled trial is difficult to conduct owing to the rarity of the disease and need to treat it early.